References
- Ahn IE, Jerussi T, Farooqui M, et al. Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib. Blood. 2016;128:1940–1943.
- de Jesus Ngoma P, Kabamba B, Dahlqvist G, et al. Occult HBV reactivation induced by ibrutinib treatment: a case report. Acta Gastroenterol Belg. 2015;78:424–426.
- Gnann JW Jr, Varicella-zoster virus: atypical presentations and unusual complications. J Infect Dis. 2002;186:S91–S98.
- Melchardt T, Weiss L, Greil R, et al. Viral infections and their management in patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54:1602–1613.
- Doki N, Miyawaki S, Tanaka M, et al. Visceral varicella zoster virus infection after allogeneic stem cell transplantation. Transpl Infect Dis. 2013;15:314–318.
- Wang Z, Ye J, Han YH. Acute pancreatitis associated with herpes zoster: case report and literature review. World J Gastroenterol. 2014;20:18053–18056.
- David DS, Tegtmeier BR, O'Donnell MR, et al. Visceral varicella-zoster after bone marrow transplantation: report of a case series and review of the literature. Am J Gastroenterol. 1998;93:810–813.
- Gracias DT, Boesteanu AC, Fraietta JA, et al. Phosphatidylinositol 3-kinase p110delta isoform regulates CD8+ T cell responses during acute viral and intracellular bacterial infections. J Immunol. 2016;196:1186–1198.
- Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370:997–1007.
- Cheah CY, Fowler NH. Idelalisib in the management of lymphoma. Blood. 2016;128:331–336.
- Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122:2539–2549.
- Sagiv-Barfi I, Kohrt HE, Czerwinski DK, et al. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci USA. 2015;112:E966–E972.
- Byrd JC, Brown JR, O'Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371:213–223.
- Verdun N. Food and drug administration. Ibrutinib Premarket Approval Medical Review for CLL. 2014. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2014/205552Orig2s000MedR.pdf.
- Chen I, Fohtung RB, Oughli HA, et al. Concurrent Ramsay Hunt syndrome and disseminated herpes zoster in a patient with relapsed chronic lymphocytic leukemia. IDCases 2016;6:79–82.